Trastuzumab and congestive heart failure: What can we learn from use in the community?

Journal of the National Cancer Institute

Volumn 104, Issue 17, 2012, Pages 1269-1270

  Geiger, Ann M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

BREAST CANCER; BREAST METASTASIS; CANCER SURVIVAL; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; DRUG SAFETY; EDITORIAL; FOLLOW UP; HEART FUNCTION; HUMAN; OVERALL SURVIVAL; PATIENT MONITORING; PERSONALIZED MEDICINE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR;

ANTHRACYCLINES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HEART FAILURE; HUMANS;

EID: 84866064063     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs342     Document Type: Editorial

References (8)

1. Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med. 2005;353(16):1734-1736. (Pubitemid 41464714)
2. Maitland ML, Schilsky RL. Clinical trials in the era of personalized oncology. CA Cancer J Clin. 2011;61(6):365-381.
3. Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012;4:CD006243.
4. Chan AL, Leung HW, Lu CL, Lin SJ. Cost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: a systematic review. Ann Pharmacother. 2009;43(2):296-303.
5. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastu-zumab clinical trials experience. J Clin Oncol. 2002;20(5):1215-1221. (Pubitemid 34177427)
6. Bowles EJ, Wellman R, Feigelson HS, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012;104(17).
7. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-1684. (Pubitemid 41464706)
8. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, pacli-taxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23(16):3676-3685.